Neuregulin-1 Protects Against Doxorubicin-Induced Apoptosis in Cardiomyocytes Through an Akt-Dependent Pathway
-
Published:2013-08-17
Issue:
Volume:
Page:379-385
-
ISSN:1802-9973
-
Container-title:Physiological Research
-
language:en
-
Short-container-title:Physiol Res
Author:
AN T., ZHANG Y., HUANG Y., ZHANG R., YIN S., GUO X., WANG Y., ZOU C., WEI B., LV R., ZHOU Q., ZHANG J.1
Affiliation:
1. Heart Failure Center, State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Abstract
In previous studies, it has been shown that recombinant human neuregulin-1(rhNRG-1) is capable of improving the survival rate in animal models of doxorubicin (DOX)-induced cardiomyopathy; however, the underlying mechanism of this phenomenon remains unknown. In this study, the role of rhNRG-1 in attenuating doxorubicin-induce apoptosis is confirmed. Neonatal rat ventricular myocytes (NRVMs) were subjected to various treatments, in order to both induce apoptosis and determine the effects of rhNRG-1 on the process. Activation of apoptosis was determined by observing increases in the protein levels of classic apoptosis markers (including cleaved caspase-3, cytochrome c, Bcl-2, BAX and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining). The activation of Akt was detected by means of western blot analysis. The study results showed that doxorubicin increased the number of TUNEL positive cells, as well as the protein levels of cleaved caspase-3 and cytochrome c, and reduced the ratio of Bcl-2/Bax. However, all of these effects were markedly antagonized by pretreament with rhNRG-1. It was then further demonstrated that the effects of rhNRG-1 could be blocked by the phosphoinositole-3-kinase inhibitor LY294002, indicating the involvement of the Akt process in mediating the process. RhNRG-1 is a potent inhibitor of doxorubicin-induced apoptosis, which acts through the PI3K-Akt pathway. RhNRG-1 is a novel therapeutic drug which may be effective in preventing further damage from occurring in DOX-induced damaged myocardium.
Publisher
Institute of Physiology of the Czech Academy of Sciences
Subject
General Medicine,Physiology
Reference27 articles.
1. BIAN Y, SUN M, SILVER M, HO KK, MARCHIONNI MA, CAGGIANO AO, STONE JR, AMENDE I, HAMPTON TG, MORGAN JP, YAN X: Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins. Am J Physiol Heart Circ Physiol 297: H1974-H1983, 2009. 2. BRISTOW MR, BILLINGHAM ME, MASON JW, DANIELS JR: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62: 873-879, 1978. 3. CHAANINE AH, HAJJAR RJ: AKT signalling in the failing heart. Eur J Heart Fail 13: 825-829, 2011. 4. CRONE SA, ZHAO YY, FAN L, GU Y, MINAMISAWA S, LIU Y, PETERSON KL, CHEN J, KAHN R, CONDORELLI G, ROSS J JR, CHIEN KR, LEE KF: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-465, 2002. 5. FANG SJ, WU XS, HAN ZH, ZHANG XX, WANG CM, LI XY, LU LQ, ZHANG JL: Neuregulin-1 preconditioning protects the heart against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Chin Med J (Engl) 123: 3597-3604, 2010.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|